CATT Study Finds No Difference Between Avastin and Lucentis in Stopping Progression of Wet Macular Degeneration
April 29, 2011
Yesterday, the New England Journal of Medicine released the much anticipated one-year results of The Comparison of AMD Treatment Trials (CATT) Study evaluating the relative effectiveness of Avastin (Bevacizumab) versus Lucentis (Ranibizumab) in stopping the progression of wet AMD and improving vision.
The study involved 1,185 patients being treated at 43 clinical centers in the United States. Patients were randomly assigned and treated with one of four regimens for a year. They received Lucentis monthly or as needed, or Avastin monthly or as needed.
The results showed that Avastin and Lucentis were equally effective and safe to use. Further, the study showed that “as needed” dosing does nearly as well (2 letter difference) as monthly injections.
To read my summary of the study, as well as Dr. Phil Rosenfeld’s editorial comments, please take a look at this link.
Click here to read the write up of the study in the New England Journal of Medicine.
Jump down to form below to submit your own comments